

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA Mexiletine for treating symptomatic myotonia in adults
with non-dystrophic myotonic disorders**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

At the scoping workshop it was noted that although there is no evidence to suggest different prevalence among ethnicities, black and ethnic minority groups are underrepresented in the population currently treated with mexiletine. However this may be associated with the reluctance of some minority groups' reluctance to receive genetic testing for diagnosis.
--

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|---|

It was noted in the workshop that access to the technology is not an issue and therefore other factors could be contributing to the underrepresentation of minority groups coming forward for treatment. This is not an issue that could be addressed by NICE through making adjustments to its process, nor could it be addressed in its recommendations.
--

3. Has any change to the draft scope been agreed to highlight potential equality issues?
No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No

Approved by Associate Director (name):Sheela Upadhyaya

Date: 22/05/2018